November 30th 2023
The IND clearance sets AMT-191 to be evaluated in a clinical trial alongside the company's gene therapies for ALS and Huntington disease.
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
PER's Breast Cancer Symposia in San Antonio
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
Updates from the Annual Hematology Meeting: Matching the Tumor with Patient Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia
Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow
Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL
Follicular Lymphoma Workshop: Forging Patient-Centric Plans with Targeted Therapies Across Lines of Care
Roger Hajjar, MD, the director of the Mass General Brigham Gene and Cell Therapy Institute, spoke about his presentation on gene therapy for cardiologists at AHA’s 2023 Scientific Sessions.
The chief research officer of the Muscular Dystrophy Association discussed the need for disease-modifying therapies in other muscular dystrophies and programs the association has announced to this end.
Maria Pia Morelli, MD, PhD, assistant professor, MD Anderson Cancer Center, discussed her work on the EVEREST-1 trial of logic-gated CAR T-cell therapy currently being evaluated in colorectal and pancreatic cancers.
Among 10 patients evaluated compared to their baseline at 1 week after receiving their final dose in the trial, 30% of patients demonstrated clinical improvement on the ADCOMS.
The postdoctoral research fellow at Cedars Sinai Medical Center discussed the future of RNA therapy in the context of research in systemic sclerosis he presented at AHA’s Scientific Sessions 2023.
Milind Desai, MD, MBA, the director of the Hypertrophic Cardiomyopathy Center and the vice chair of the Heart Vascular Thoracic Institute at the Cleveland Clinic, discussed the design of Tenaya Therapeutics’ clinical trial evaluating TN-201.
Eli Lilly’s small interfering RNA therapy showed significant serum reductions with a single dose while remaining well-tolerated. A larger phase 2 study is currently ongoing.